Literature DB >> 23583229

Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?

D M Gujral, G Lloyd, S Bhattacharyya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23583229     DOI： 10.1016/j.clon.2013.03.006

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  3 in total

1.  Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.

Authors:  Christine C Davis; Amelia Zelnak; J William Eley; Daniel A Goldstein; Jeffrey M Switchenko; Trevor McKibbin
Journal:  Ann Pharmacother       Date:  2016-06-15       Impact factor: 3.154

2.  Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer.

Authors:  Mariana Chavez-MacGregor; Jiangong Niu; Ning Zhang; Linda S Elting; Benjamin D Smith; Jose Banchs; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

3.  Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series.

Authors:  Icro Meattini; Sara Cecchini; Cristina Muntoni; Vieri Scotti; Carla De Luca Cardillo; Monica Mangoni; Pierluigi Bonomo; Jacopo Nori; Donato Casella; Roberta Simoncini; Lorenzo Orzalesi; Simonetta Bianchi; Lorenzo Livi
Journal:  Med Oncol       Date:  2014-02-18       Impact factor: 3.064
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.